Phuong K. Morrow

3.2k total citations
65 papers, 1.8k citations indexed

About

Phuong K. Morrow is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Phuong K. Morrow has authored 65 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 13 papers in Genetics. Recurrent topics in Phuong K. Morrow's work include Neutropenia and Cancer Infections (18 papers), Blood disorders and treatments (10 papers) and Cancer Treatment and Pharmacology (10 papers). Phuong K. Morrow is often cited by papers focused on Neutropenia and Cancer Infections (18 papers), Blood disorders and treatments (10 papers) and Cancer Treatment and Pharmacology (10 papers). Phuong K. Morrow collaborates with scholars based in United States, Australia and United Kingdom. Phuong K. Morrow's co-authors include Gabriel N. Hortobágyi, Maureen Reiner, Gary H. Lyman, Jeffrey Crawford, Daniel J. Booser, Laura J. Havrilesky, Francisco J. Esteva, Jacob Garcia, Richard Barron and Neelima Denduluri and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Phuong K. Morrow

62 papers receiving 1.7k citations

Peers

Phuong K. Morrow
Jacqueline M. Lafky United States
Αngelos Koutras Greece
Lissandra Dal Lago Belgium
Daniel A. Nikcevich United States
Neelima Denduluri United States
Howard M. Gross United States
Michael Danso United States
Jean‐Emmanuel Kurtz France
Douglas E. Merkel United States
Steen Werner Hansen Denmark
Jacqueline M. Lafky United States
Phuong K. Morrow
Citations per year, relative to Phuong K. Morrow Phuong K. Morrow (= 1×) peers Jacqueline M. Lafky

Countries citing papers authored by Phuong K. Morrow

Since Specialization
Citations

This map shows the geographic impact of Phuong K. Morrow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phuong K. Morrow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phuong K. Morrow more than expected).

Fields of papers citing papers by Phuong K. Morrow

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phuong K. Morrow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phuong K. Morrow. The network helps show where Phuong K. Morrow may publish in the future.

Co-authorship network of co-authors of Phuong K. Morrow

This figure shows the co-authorship network connecting the top 25 collaborators of Phuong K. Morrow. A scholar is included among the top collaborators of Phuong K. Morrow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phuong K. Morrow. Phuong K. Morrow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Carter, Bing Z., Po Yee Mak, Wenjing Tao, et al.. (2023). Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer Journal. 13(1). 57–57. 20 indexed citations
2.
Carter, Bing Z., Po Yee Mak, Wenjing Tao, et al.. (2022). Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic–Resistant AML and AML Stem Cells. Molecular Cancer Therapeutics. 21(6). 879–889. 11 indexed citations
3.
Wei, Andrew H., Andrew W. Roberts, Andrew Spencer, et al.. (2020). Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews. 44. 100672–100672. 152 indexed citations
4.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(11). S1125–S1126. 3 indexed citations
5.
Crawford, Jeffrey, Neelima Denduluri, Debra A. Patt, et al.. (2019). Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Supportive Care in Cancer. 28(2). 925–932. 40 indexed citations
6.
Govindan, Ramaswamy, Marwan Fakih, Gerald S. Falchook, et al.. (2019). OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC. Journal of Thoracic Oncology. 14(10). S208–S208. 30 indexed citations
7.
8.
Denduluri, Neelima, Gary H. Lyman, Yunfei Wang, et al.. (2018). Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer. Clinical Breast Cancer. 18(5). 380–386. 54 indexed citations
9.
Benveniste, Ana P., et al.. (2016). Surveillance of women with a personal history of breast cancer by tumour subtype. Clinical Radiology. 72(3). 266.e1–266.e6. 3 indexed citations
10.
Lyman, Gary H., Maureen Reiner, Phuong K. Morrow, & Jeffrey Crawford. (2015). The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy. Annals of Oncology. 26(7). 1452–1458. 28 indexed citations
11.
Yang, Bingbing, et al.. (2015). Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemotherapy and Pharmacology. 75(6). 1199–1206. 28 indexed citations
12.
Escalante, Carmen P., Christina Meyers, James M. Reuben, et al.. (2014). A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients. The Cancer Journal. 20(1). 8–14. 61 indexed citations
13.
Harrold, John M., Philippe Jacqmin, Per Olsson, et al.. (2014). Translational Modeling to Identify Human Dosing of Filgrastim to Improve Overall Survival (OS) in Acute Radiation Syndrome (ARS). Blood. 124(21). 690–690.
14.
Havrilesky, Laura J., et al.. (2014). A review of relative dose intensity and survival in patients with metastatic solid tumors. Critical Reviews in Oncology/Hematology. 93(3). 203–210. 110 indexed citations
15.
Bayraktar, Soley, Angelica M. Gutierrez‐Barrera, Heather Lin, et al.. (2013). Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clinical & Experimental Metastasis. 30(5). 631–642. 26 indexed citations
16.
Morrow, Phuong K., A. Broxson, Mark F. Munsell, et al.. (2013). Effect of Age and Race On Quality of Life in Young Breast Cancer Survivors. Clinical Breast Cancer. 14(2). e21–e31. 45 indexed citations
17.
Escalante, Carmelita P., et al.. (2010). Outcomes of a Cancer-Related Fatigue Clinic in a Comprehensive Cancer Center. Journal of Pain and Symptom Management. 39(4). 691–701. 34 indexed citations
18.
Morrow, Phuong K., Jeffery Tarrand, Sarah Taylor, et al.. (2009). Effects of chronic hepatitis C infection on the treatment of breast cancer patients. Annals of Oncology. 21(6). 1233–1236. 16 indexed citations
19.
Morrow, Phuong K., Francisco Zambrana, & Francisco J. Esteva. (2009). Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Research. 11(4). 207–207. 37 indexed citations
20.
Morrow, Phuong K. & Richard L. Theriault. (2006). Pregnancy After the Diagnosis of Breast Cancer. Clinical Breast Cancer. 7(2). 173–175. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacqueline M. Lafky Breakdown of academic impact, for papers by Αngelos Koutras Breakdown of academic impact, for papers by Lissandra Dal Lago Breakdown of academic impact, for papers by Daniel A. Nikcevich Breakdown of academic impact, for papers by Neelima Denduluri Breakdown of academic impact, for papers by Howard M. Gross Breakdown of academic impact, for papers by Michael Danso Breakdown of academic impact, for papers by Jean‐Emmanuel Kurtz Breakdown of academic impact, for papers by Douglas E. Merkel Breakdown of academic impact, for papers by Steen Werner Hansen
Rankless by CCL
2026